Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Abstract

Ribavirin was discovered nearly 40 years ago as a broad-spectrum antiviral drug. Recent data suggest that ribavirin may also be an effective cancer therapy. In this case, ribavirin targets an oncogene, the eukaryotic translation initiation factor eIF4E, elevated in approximately 30% of cancers including many leukemias and lymphomas. Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E. In a phase II clinical trial, ribavirin treatment led to substantial clinical benefit in patients with poor-prognosis acute myeloid leukemia (AML). Here molecular targeting of eIF4E correlated with clinical response. Ribavirin also targets a key enzyme in the guanosine biosynthetic pathway, inosine monophosphate dehydrogenase (IMPDH), and also modulates immunity. Parallels with known antiviral mechanisms could be informative; however, after 40 years, these are not entirely clear. The antiviral effects of ribavirin appear cell-type specific. This variation likely arises for many reasons, including cell specific variations in ribavirin metabolism as well as virus specific factors. Thus, it seems that the mechanisms for ribavirin action in cancer therapy may also vary in terms of the cancer/tissue under study. Here we review the anticancer activities of ribavirin and discuss the possible utility of incorporating ribavirin into diverse cancer therapeutic regimens.

Keywords:

• eIF4E
• Leukemia
• Translation
• mRNA export

Acknowledgements

The authors thank Alex Kentsis, Maria Salvato, and Nadeem Siddiqui for helpful comments on the manuscript.

Declaration of interest: Research was supported by NIH R01 80728, RO1 98571, and a grant from the Translational Research Program of the Leukemia and Lymphoma Society. IRIC receives infrastructure support from the CIHR and FRSQ. K.L.B.B. holds a Canada Research Chair.